Operating cash flow jumped 34.7% while NPAT stalled at NZ$5.6m

What changed

Revenue rose 3.9% to NZ$259.9m, with EBIT up 7.8% to NZ$16.1m and PBT up 5.6% to NZ$11.1m. NPAT attributable to shareholders was essentially flat at NZ$5.6m (+0.7%). Operating cash flow climbed 34.7% to NZ$25.3m while capex fell to NZ$2.2m (0.8% of revenue) from NZ$3.2m, lifting pre-lease free cash flow to NZ$23.1m from NZ$15.6m. Cash on hand rose to NZ$28.9m; although gross borrowings increased to NZ$34.5m, net debt fell sharply to NZ$5.7m from NZ$12.9m. An interim dividend of 2.5 cents per share was declared (HY24 comparator not disclosed in the supplied data). Segment mix shifted modestly: Medical Services revenue grew to NZ$77.7m (29.9% of the mix, up 2.4pp) while Pharmacy Services revenue was near flat at NZ$182.2m.

What matters

• Cash conversion was the standout. OCF of NZ$25.3m against NPAT of NZ$5.6m, with OCF up 35% on only 4% revenue growth, is the strongest data point in the release. Receivable days improved from 12.9 to 8.9, which accounts for much of the uplift.
• NPAT looked flat only because of a prior-period discontinued operation. HY24 reported NPAT of NZ$5.6m included the effect of a NZ$4.3m after-tax discontinued-operation contribution within profit-for-the-period; continuing-operations profit actually rose from NZ$7.7m to NZ$8.1m (+5.5%). On a like-for-like continuing basis, PBT growth of 5.6% is the cleaner operating read — tax rates were effectively unchanged at ~27.2%.
• Balance sheet direction is clearly strengthening. Net debt approximately halved despite a 3.1% lift in gross borrowings, and equity grew 4.1% to NZ$169.3m. Leverage headroom has improved materially, although net debt to an EBITDA measure cannot be computed because EBITDA is not disclosed.

Expectations

No formal forward-work disclosure, guidance, or stated targets were provided in the release excerpts. Against FY24 shape, HY24 was 49.6% of full-year revenue and 47.7% of full-year NPAT, so the historical half-year split was broadly even rather than second-half weighted. Annualised HY25 revenue of NZ$519.8m sits ~3.1% above FY24's NZ$503.9m, consistent with the stated revenue trend. Annualised NPAT at ~NZ$11.3m would land below FY24's NZ$12.0m unless Medical Services mix continues to lift margins in H2 — the release does not support an explicit H2 call either way.

Quality of result

The operating result looks reasonable in quality: EBIT growth outpaced revenue, the effective tax rate was stable, and Medical Services (the higher-margin segment at ~10.6% margin versus Pharmacy's ~4.9%) drove the mix improvement. However, the cash performance is partly working-capital-assisted: the NZ$4.9m fall in trade debtors is a material swing that is unlikely to repeat at the same magnitude. Stripping that, underlying cash generation is still healthier than prior, but pre-lease FCF at 4.1x NPAT overstates the durable run-rate. Post-lease FCF cannot be computed from the supplied data, which matters for a pharmacy and medical centre network with meaningful lease obligations. The interim dividend (NPAT payout ~63.6%, pre-lease FCF payout ~15.6%) is covered on pre-lease cash but its coverage on a post-lease basis is unclear.

Unresolved

• EBITDA, free cash flow, and net debt to EBITDA are not disclosed, limiting comparability with peers and history.
• Lease payments are not broken out in the supplied excerpts, so post-lease FCF and true dividend coverage are unknown.
• No forward guidance, forward-work book, or stated FY25 targets were provided; the strategic read on whether mix-shift to Medical Services continues is unsupported by the release.
• The HY24 prior dividend and therefore the year-on-year dividend trajectory are not in the supplied data.
• Segment result of NZ$8.2m for Medical Services versus NZ$8.9m for Pharmacy is disclosed, but cost allocation and whether Medical margins are sustainable versus pharmacy-led group costs is not clarified.

This briefing cannot assess post-lease cash economics, peer-relative valuation, or management's forward outlook because EBITDA, lease cash flows, NTA per share, and any guidance were not provided in the supplied materials.

Key metrics

Segment breakdown

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.